DivestmentApr 28, 2026, 04:17 PM
ANAB Completes First Tracks Biotherapeutics Spin-Off
AI Summary
ANAPTYSBIO, INC. completed the spin-off of its subsidiary, First Tracks Biotherapeutics, Inc., as a pro rata dividend to stockholders on April 20, 2026. In connection with this divestment, Eric Loumeau, Paul Lizzul, M.D., Ph.D., and Dennis Mulroy separated from the company. The board of directors was also reclassified due to the departure of four members, ensuring equal apportionment across its three classes. This 10-K/A filing provides detailed corporate governance, executive compensation for 2025, and a summary of 2025 corporate milestones.
Key Highlights
- First Tracks Biotherapeutics, Inc. spun off via pro rata dividend on April 20, 2026.
- Eric Loumeau, Paul Lizzul, M.D., Ph.D., and Dennis Mulroy departed on April 20, 2026.
- Board reclassified into Class I (Nodelman, Gray), Class II (Faga, Orwin), Class III (Renton, Schmid).
- Completed rosnilimab Phase 2b trial for rheumatoid arthritis in 2025.
- Out-licensed imsidolimab to Vanda Pharmaceuticals in 2025.
- Announced intent to separate biopharma operations from royalty assets by year-end 2026.
- John Orwin's 2025 total compensation was $370,233.
- John P. Schmid's 2025 total compensation was $336,983.
Price Impact
More from ANAB